Jupiter Neurosciences Inc
Follow $JUNS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $JUNS by emailVeridion Score
BETALOW CONF · 5 of 6 factors measuredsnapshot unavailable for JUNS. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is JUNS moving today?
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
JUNS overview
Related filings and maps
Congress activity in JUNS
No receipt-qualified filings found.
JUNS contract awards, year to date.
Public federal awards linked to this ticker.
JUNS lobbying filings, year to date.
Registered lobbying filings matched to Jupiter Neurosciences Inc.